D&D Pharmatech’s US unit to work with NIH, Johns Hopkins for Parkinson’s research

Neuraly, a U.S. subsidiary of D&D Pharmatech, has announced a collaboration with the National Institute on Aging (NIA) under the National Institutes of Health (NIH) and Johns Hopkins University School of Medicine to advance biomarker research using serum samples from patients involved in the phase 2 clinical trial of NLY01, a treatment for Parkinson’s disease. NLY01, a long-acting GLP-1 receptor agonist, is being developed as a therapeutic for neurodegenerative diseases, including Parkinson’s disease. he drug recently completed a global phase 2 clinical trial, showing therapeutic effects, particularly in younger patients under the age of 60. Read more >>